This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Key recent developments in the program include: The first two years of the MDPNP only covered retail-dispensed therapies but starting in this selection...
Field Medical teams often rely on relationship length, contact frequency, and number of interactions as indicators of strong engagement. But do these drivers...
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...
